Search This Blog

Thursday, May 14, 2026

Biogen moves Alzheimer drug into registrational development after Phase 2 misses primary endpoint

 

Biogen moves Alzheimer drug diranersen (BIIB080) into registrational development after Phase 2 CELIA misses primary dose‑response endpoint but shows tau reduction

  • Topline Phase 2 CELIA data reported cognitive benefit for Alzheimer’s candidate diranersen (BIIB080).
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)